ALLR stock news · Allarity Therapeutics
Get alerts for ALLR
Follow Allarity Therapeutics (ALLR) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ALLRAllarity Therapeutics is adding three groups of ovarian cancer patients to its Phase 2 trial for stenoparib.
Good for ALLRAllarity is expanding its stenoparib study to 3 ovarian cancer groups. The wider test is favorable for development, but the added groups have no reported results yet.
Allarity Therapeutics, Inc. shares news about its drug technology and research progress.
Good for ALLRAllarity Therapeutics said its drug-response technology, patents, and lab capabilities have advanced. This supports stenoparib development and could open partnership opportunities, a positive sign.
Allarity Therapeutics, Inc. says it is expanding its lab facilities.
NeutralAllarity expanded its lab work to include proteomics and cell line research. The filing gives no results or business outcomes, so this news does not change its outlook.
Allarity Therapeutics, Inc. says its subsidiary is planning to go public.
NeutralAllarity said a newly formed SPAC filed an S-1 to offer units. That filing alone does not change how we read Allarity.